Payment overview · 2025
General Payments
$474.13
20 reported records · 7 companies
Healthcare provider profile · identity verified
Marguerite Bernard, MD
Allopathic & Osteopathic Physicians|Internal Medicine · BRONX, NY · NPI 1952374613
Verified facts
What the public records show
CMS Open Payments records show Marguerite Bernard, MD received $474.13 in general payments during 2025 across 20 reported records.
ViiV Healthcare Company accounted for 39.9% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 9 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Biktarvy, Dovato, Mounjaro, Ozempic.
Gilead Sciences, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Biktarvy as an associated drug or biological on 8065 records involving 2759 distinct recipient NPIs. Public Medicare Part D data also shows 38 claims for Biktarvy by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 57 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 89 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 165 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 52 claims for Rybelsus by this doctor in 2024.
ViiV Healthcare Company reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported DOVATO as an associated drug or biological on 18732 records involving 3540 distinct recipient NPIs. Public Medicare Part D data also shows 26 claims for Dovato by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ViiV Healthcare Company | Unresolved — no canonical attribution shown | $188.99 | 39.9% | 7 | 2025 |
| Gilead Sciences, Inc. | Unresolved — no canonical attribution shown | $81.33 | 17.1% | 4 | 2025 |
| EMD Serono, Inc. | Unresolved — no canonical attribution shown | $55.99 | 11.8% | 3 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $51.88 | 10.9% | 2 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $39.81 | 8.4% | 2 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $31.25 | 6.6% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $24.88 | 5.2% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $474.13 | 20 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| DOVATO Normalized: dovato |
Drug | ViiV Healthcare Company | $111.56 | 4 | 2025 |
Source payment records
|
|||||
| CABENUVA Normalized: cabenuva |
Drug | ViiV Healthcare Company | $74.02 | 3 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $51.88 | 2 | 2025 |
Source payment records
|
|||||
| PIFELTRO Normalized: pifeltro |
Drug | Merck Sharp & Dohme LLC | $39.81 | 2 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $31.25 | 1 | 2025 |
Source payment records
|
|||||
| APRETUDE Normalized: apretude |
Drug | ViiV Healthcare Company | $27.53 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $24.88 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $24.32 | 1 | 2025 |
Source payment records
|
|||||
| Biktarvy Normalized: biktarvy |
Drug | Gilead Sciences, Inc. | $19.97 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| Biktarvy biktarvy |
2025 | Biktarvy | 2024 | 38 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| DOVATO dovato |
2025 | Dovato | 2024 | 26 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 17 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 165 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Gilead Sciences, Inc. Exact reporting entity; no affiliate inference |
2025 | Biktarvy open payments reported associated product |
CMS Open Payments — General Payments 8065 supporting records · 2759 recipient NPIs · example record 1234350766 |
Biktarvy · 2024 Exact normalized brand match · 1 Part D row |
38 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
57 | 17 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
89 | 16 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
165 | 27 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
52 | 11 |
| ViiV Healthcare Company Exact reporting entity; no affiliate inference |
2025 | DOVATO open payments reported associated product |
CMS Open Payments — General Payments 18732 supporting records · 3540 recipient NPIs · example record 1189508902 |
Dovato · 2024 Exact normalized brand match · 1 Part D row |
26 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 730 | 200 |
| Amlodipine Besylate | Amlodipine Besylate | 421 | 113 |
| Losartan Potassium | Losartan Potassium | 407 | 104 |
| Pioglitazone Hcl | Pioglitazone Hcl | 379 | 96 |
| Omeprazole | Omeprazole | 345 | 93 |
| Metformin Hcl | Metformin Hcl | 286 | 74 |
| Hydrochlorothiazide | Hydrochlorothiazide | 264 | 77 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 258 | 82 |
| Lisinopril | Lisinopril | 205 | 54 |
| Metformin Hcl Er | Metformin Hcl | 181 | 47 |
| Famotidine | Famotidine | 178 | 41 |
| Ozempic | Semaglutide | 165 | 27 |
| Nifedipine Er | Nifedipine | 164 | 40 |
| Gabapentin | Gabapentin | 156 | 44 |
| Metoprolol Succinate | Metoprolol Succinate | 137 | 38 |
| Simvastatin | Simvastatin | 136 | 35 |
| Alendronate Sodium | Alendronate Sodium | 134 | 35 |
| Diclofenac Sodium | Diclofenac Sodium | 127 | 41 |
| Montelukast Sodium | Montelukast Sodium | 118 | 38 |
| Trazodone Hcl | Trazodone Hcl | 108 | 23 |
| Ezetimibe | Ezetimibe | 106 | 32 |
| Metoprolol Tartrate | Metoprolol Tartrate | 104 | 25 |
| Levothyroxine Sodium | Levothyroxine Sodium | 100 | 27 |
| Fluticasone Propionate | Fluticasone Propionate | 92 | 25 |
| Pantoprazole Sodium | Pantoprazole Sodium | 92 | 30 |
| Januvia | Sitagliptin Phosphate | 90 | 21 |
| Trulicity | Dulaglutide | 89 | 16 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 88 | 29 |
| Alcohol Prep Pads | Alcohol Antiseptic Pads | 86 | 31 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 81 | 23 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 78 | 31 |
| Ammonium Lactate | Ammonium Lactate | 66 | 15 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 66 | 21 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 65 | 14 |
| Chlorthalidone | Chlorthalidone | 65 | 16 |
| Meclizine Hcl | Meclizine Hcl | 64 | 23 |
| Furosemide | Furosemide | 62 | 18 |
| Vascepa | Icosapent Ethyl | 59 | 14 |
| Jardiance | Empagliflozin | 57 | 17 |
| Tamsulosin Hcl | Tamsulosin Hcl | 56 | 16 |
| Rybelsus | Semaglutide | 52 | 11 |
| Folic Acid | Folic Acid | 49 | 11 |
| Linzess | Linaclotide | 49 | 12 |
| Doxazosin Mesylate | Doxazosin Mesylate | 48 | 12 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 48 | 11 |
| Enalapril Maleate | Enalapril Maleate | 47 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 46 | suppressed |
| Clotrimazole | Clotrimazole | 46 | 11 |
| Glimepiride | Glimepiride | 45 | suppressed |
| Atenolol | Atenolol | 43 | 14 |
| Carvedilol | Carvedilol | 43 | 13 |
| Novolog Flexpen | Insulin Aspart | 42 | 13 |
| Valacyclovir | Valacyclovir Hcl | 42 | suppressed |
| Eliquis | Apixaban | 41 | suppressed |
| Biktarvy | Bictegrav/Emtricit/Tenofov Ala | 38 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 38 | suppressed |
| Torsemide | Torsemide | 38 | 12 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 36 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 35 | 16 |
| Breo Ellipta | Fluticasone/Vilanterol | 32 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 32 | suppressed |
| Meloxicam | Meloxicam | 32 | suppressed |
| Metformin Er Gastric | Metformin Hcl | 31 | suppressed |
| Ibuprofen | Ibuprofen | 30 | 13 |
| Tradjenta | Linagliptin | 30 | suppressed |
| Valsartan | Valsartan | 30 | suppressed |
| Alcohol Swabs | Alcohol Antiseptic Pads | 29 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 29 | suppressed |
| Easy Touch Alcohol Prep Pads | Alcohol Antiseptic Pads | 28 | suppressed |
| Lidocaine | Lidocaine | 27 | suppressed |
| Dovato | Dolutegravir Sodium/Lamivudine | 26 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 25 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 25 | 12 |
| Arnuity Ellipta | Fluticasone Furoate | 24 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 24 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 24 | suppressed |
| Alcohol Pads | Alcohol Antiseptic Pads | 23 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 23 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 22 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 22 | suppressed |
| Mirtazapine | Mirtazapine | 22 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 21 | suppressed |
| Naproxen | Naproxen | 21 | suppressed |
| Potassium Chloride | Potassium Chloride | 21 | suppressed |
| Atenolol-Chlorthalidone | Atenolol/Chlorthalidone | 20 | suppressed |
| Baclofen | Baclofen | 20 | suppressed |
| Myrbetriq | Mirabegron | 19 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 19 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 19 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 18 | suppressed |
| Glipizide | Glipizide | 18 | suppressed |
| Levetiracetam | Levetiracetam | 18 | suppressed |
| Advair Hfa | Fluticasone Propion/Salmeterol | 17 | suppressed |
| Mounjaro | Tirzepatide | 17 | suppressed |
| Pro Comfort Alcohol Pads | Alcohol Antiseptic Pads | 17 | suppressed |
| Glipizide Er | Glipizide | 16 | suppressed |
| Lovastatin | Lovastatin | 16 | suppressed |
| Single Use Swab | Alcohol Antiseptic Pads | 16 | suppressed |
| Methimazole | Methimazole | 15 | suppressed |
| Nyamyc | Nystatin | 15 | suppressed |
| Phenobarbital | Phenobarbital | 15 | suppressed |
| Pregabalin | Pregabalin | 15 | suppressed |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 15 | suppressed |
| Spironolactone | Spironolactone | 15 | suppressed |
| Insulin Aspart Flexpen | Insulin Aspart | 14 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 14 | suppressed |
| Juluca | Dolutegravir/Rilpivirine | 14 | suppressed |
| Enalapril-Hydrochlorothiazide | Enalapril/Hydrochlorothiazide | 13 | suppressed |
| Fosinopril Sodium | Fosinopril Sodium | 13 | suppressed |
| Ultra-Fine Nano Pen Needle | Pen Needle, Diabetic | 13 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 13 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 12 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 12 | suppressed |
| Icosapent Ethyl | Icosapent Ethyl | 12 | suppressed |
| Risperidone | Risperidone | 12 | suppressed |
| Semglee (Yfgn) Pen | Insulin Glargine-Yfgn | 12 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 12 | suppressed |
| Xarelto | Rivaroxaban | 12 | suppressed |
| Allopurinol | Allopurinol | 11 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $474.13 · 20 records | ViiV Healthcare Company | APRETUDE, Biktarvy, CABENUVA, DOVATO, Dexcom G6 Transmitter, MOUNJARO, Ozempic, PIFELTRO, ZEPBOUND | 7 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Biktarvy play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Gilead Sciences, Inc.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error